Electronic Supplementary Material (ESI) for New Journal of Chemistry. This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2023

# Supplementary Data

# Ring expansion/ opening reactions of epoxy ene-amides: Access to

azabicyclononene, tetrahydropyridine and tetrazole scaffolds

Suraj and K. C. Kumara Swamy\*

School of Chemistry, University of Hyderabad,

Hyderabad -500046, Telangana, India

# e-mail: kckssc@uohyd.ac.in, kckssc@yahoo.com

	Contents	Page No.
1	General methods	S1-S2
2	Synthesis of epoxy benzene sulfonamide, chloro-acrylaldehydes, and 3-	S2
	chloro-2,3-diphenylacrylaldehyde	
3	Optimization of reaction conditions	S2-S4
4	Synthesis of compounds 3aa-gb, 3la, 4aa-gb, 5aa, 5ba-bb, 5ca-cb, 5db,	S5-S31
	<b>5ea-eb, 5fa, 5ga</b> , 6 <b>hc, 6ic, 6jc, 6kc</b> , and <b>7la</b>	
5	ORTEPs of 4aa, 4db, 5ba, 5cb, 6hc, 7la (Figures S1-S6)	S32-S37
6	References	S38
7	<sup>1</sup> H and <sup>13</sup> C{ <sup>1</sup> H} NMR spectra of all new compounds (Figures S7-S94)	S39-S82
	[order: 3aa-gb, 3la, 4aa-gb, 5aa, 5ba-bb, 5ca-cb, 5db, 5ea-eb, 5fa, 5ga,	
	6hc 6ic, 6jc, 6kc, 7la]	

# 1. General Methods:

All chemicals were procured from Aldrich or local manufacturers and used Further without any purification unless noted. Chemicals were purified when required according to standard procedures.<sup>1</sup> All reactions, unless stated otherwise, were performed in a dry nitrogen atmosphere. <sup>1</sup>H and <sup>13</sup>C{<sup>1</sup>H} NMR spectra were recorded using 5 mm tubes [field strengths: 400 and 100 MHz for <sup>1</sup>H/<sup>13</sup>C using 400 MHz NMR spectrometer; 500 and 125 MHz for <sup>1</sup>H, <sup>13</sup>C{<sup>1</sup>H} using 500 MHz NMR spectrometer] in CDCl<sub>3</sub> solution (unless specified otherwise) with shifts referenced to SiMe<sub>4</sub> [ = 0 for <sup>1</sup>H, <sup>13</sup>C{<sup>1</sup>H}]. All *J* values are in Hz. Infrared spectra were recorded neat or by using KBr pellets on an FT/IR spectrometer. Melting points were determined by using a local hot-stage melting point apparatus and are uncorrected. For TLC, glass micro slides were coated with silica-gel-GF254 (mesh size 75) and spots were identified using iodine or UV chamber as appropriate. For column chromatography, silica gel of 100-200 mesh size was used. Mass spectra were recorded using HRMS (ESI-TOF analyzer) equipment. X-ray data for **4aa**, **4db**, **5ba**, **5cb**, **6hc** and **7la** were collected at 298 K on a Bruker AXS-SMART or OXFORD diffractometer using Mo-K<sub>a</sub> (= 0.71073 Å) radiation. Structures were solved and refined using standard methods.<sup>2</sup> CCDC nos. are 2237334-2237338 and 2253326.

#### 2. Synthesis of epoxy benzene sulfonamides (1a-1l) and chloro-acrylaldehydes (2a-2c)

The epoxy benzene sulfonamides **1a-11** and **chloro-acrylaldehydes 2a-2c** used in the present study were prepared by using known literature procedures.<sup>3-6</sup>



#### 3. Optimization of reaction conditions for the synthesis of 4 and 5

The initial reaction was performed between *N*-oxiranylmethyl benzenesulfonamide **1a** and 3chloro-2,3-diphenylacrylaldehyde **2a** in the presence of  $K_2CO_3$  in DMF solvent at 80 °C. We were able to isolate intermediate **3aa**.<sup>7</sup> The intermediate **3aa** was initially treated with BF<sub>3</sub>·OEt<sub>2</sub> (50 mol%) in CHCl<sub>3</sub> at room temperature (25 °C) for 5 h and gave the unexpected product dioxa-9-azabicyclonon-3-ene **4aa** [cf. Figure S1 for **4aa**, X-ray] in 78% yield (Table S1, entry 1). Based on this result, we screened Lewis acid catalyst, solvent, additive, reaction temperature, reaction time, and quantity of additive (Table S1). First, the effectiveness of various Lewis acid catalysts such as  $BF_3 OEt_2$ ,  $Zn(OTf)_2$ , NaOTf, AgOTf, Cu(OTf)\_2, SnCl\_2, and TiCl\_4 was screened (entries 2-7) and  $BF_3 OEt_2$  was proven to be the best. Even 3 h reaction time was sufficient (entry 8). Next, we checked the effectiveness of solvents such as DCM, DCE, CH\_3CN, THF, PEG-400, DMF and DMSO (entries 9-15). The reduction of mol% of catalyst loading (20 mol%) did not affect the yield of the product **4aa** appreciably (entry 16). When we added TMSN<sub>3</sub> as an additive, the tetrazole derivative **5aa** was obtained as the sole product (85% yield, entry 17). We investigated the effectiveness of other Lewis acids such as  $SnCl_2$  and  $Cu(OTf)_2$  (entry 18 and 19) but these were not as good as  $BF_3 OEt_2$ . Changing the solvent to DCM marginally lowered the yield to 80% (entry 20). Absence of the Lewis acid catalyst did not lead to either **4aa** or **5aa** (entry 21).

Table S1. Optimization of reaction conditions<sup>a</sup>

Ph <sup>S</sup> N H	Ph Ph	MF Co3 DMF C S N O H Ph Ph Cataly Solve	nt Ph Ph Ph Ph Ph	
1	2	3	4	5

Entry	Catalyst	Additive	Solvent	Temp (°C)	Time (h)	Yield of	Yield of
						$4aa (\%)^{b}$	5 <b>aa</b> (%)
1	BF <sub>3</sub> OEt <sub>2</sub>		CHCl <sub>3</sub>	25	5	78	
2	Zn(OTf) <sub>2</sub>		CHCl <sub>3</sub>	25	5		
3	Na(OTf)		CHCl <sub>3</sub>	25	5		
4	Ag(OTf)		CHCl <sub>3</sub>	25	5		
5	Cu(OTf) <sub>2</sub>		CHCl <sub>3</sub>	25	5	40	
6	SnCl <sub>2</sub>		CHCl <sub>3</sub>	25	5	55	
7	TiCl <sub>4</sub>		CHCl <sub>3</sub>	25	5		

8	BF <sub>3</sub> OEt <sub>2</sub>		CHCl <sub>3</sub>	25	3	78	
9	BF <sub>3</sub> OEt <sub>2</sub>		DCM	25	3	72	
10	BF <sub>3</sub> <sup>•</sup> OEt <sub>2</sub>		DCE	25	3	20	
11	BF <sub>3</sub> <sup>·</sup> OEt <sub>2</sub>		CH <sub>3</sub> CN	25	3	30	
12	BF <sub>3</sub> <sup>•</sup> OEt <sub>2</sub>		THF	25	3		
13	BF <sub>3</sub> <sup>•</sup> OEt <sub>2</sub>		PEG-400	25	3		
14	BF <sub>3</sub> <sup>•</sup> OEt <sub>2</sub>		DMF	25	3		
15	BF <sub>3</sub> <sup>•</sup> OEt <sub>2</sub>		DMSO	25	3		
16	BF <sub>3</sub> <sup>•</sup> OEt <sub>2</sub>		CHCl <sub>3</sub>	25	3	78	
17	BF <sub>3</sub> <sup>•</sup> OEt <sub>2</sub>	TMSN <sub>3</sub>	CHCl <sub>3</sub>	25	3		85
18	SnCl <sub>2</sub>	TMSN <sub>3</sub>	CHCl <sub>3</sub>	25	3		65
19	Cu(OTf) <sub>2</sub>	TMSN <sub>3</sub>	CHCl <sub>3</sub>	25	3		60
20	BF <sub>3</sub> <sup>•</sup> OEt <sub>2</sub>	TMSN <sub>3</sub>	DCM	25	3		80
21		TMSN <sub>3</sub>	CHCl <sub>3</sub>	25	3		

<sup>a</sup>Reaction conditions: **3aa** (83.9 mg, 0.20 mmol), with catalyst (50 mol % for entries 1-15 and 20 mol% for entries 16-21), and additive (Me<sub>3</sub>SiN<sub>3</sub>, 52.6  $\mu$ L, 2.0 equiv) in dry CHCl<sub>3</sub> (3.0 mL) at 25 °C (rt). Yields given are after isolation.

## 4 (a). General procedure for the synthesis of compounds 3aa-gb and 3la:

Substrate **3ca** was prepared by following the procedure described in our previous work.<sup>7</sup> The compounds **3aa-ab**, **3ba-bb**, **3cb**, **3da-db**, **3ea-eb**, **3fa-fb**, **3ga-gb** and **3lb** are new.



To a mixture of 3-chloro-2,3-diphenylacrylaldehyde **2a** (48.5 mg, 0.20 mmol 1.0 equiv), K<sub>2</sub>CO<sub>3</sub> (55.2 mg, 0.40 mmol, 2.0 equiv) in dry DMF (5 mL), *N*-(oxiran-2-ylmethyl)benzenesulfonamide **1a** (64.0 mg, 0.30 mmol, 1.5 equiv), was added. The resulting reaction mixture was heated for 2 h on an oil bath maintained at 80 °C. After the completion of the reaction as monitored by TLC, ethyl acetate (30 mL) was added and the solution was washed with water (3 × 30 mL), then with brine solution (3 × 15 mL); the aqueous layer was extracted with ethyl acetate (3 × 20 mL). The combined organic portion was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> then the solvent was evaporated under the reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: hexane/ethyl acetate 9: 1) to obtain compound **3aa**.as a mixture of *E* and *Z* isomers (1:25 ratio). Crystallization was done from an ethyl acetate-hexane mixture (1:20). Other compounds were prepared similarly.

(*E*)-*N*-(*oxiran-2-ylmethyl*)-*N*-(*3-oxo-2,3-diphenylprop-1-en-1-yl*)*benzenesulfonamide* (3aa). Following the general procedure, the reaction of 1a (64.0 mg, 0.30 mmol) with 2a (48.5 mg, 0.20



mmol),  $K_2CO_3$  (55.2 mg, 0.40 mmol), after column chromatography (EtOAc:hexane = 1:9) afforded **3aa** as a white solid. Yield 69 mg (82%). Mp 103-104 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.85-7.82 (m, 2H), 7.74-7.70 (m,

3H), 7.63-7.59 (m, 2H), 7.57-7.53 (m, 2H), 7.46-7.43 (m, 2H), 7.32-7.29 (m,

3H), 7.05-7.02 (m, 2H), 3.36-3.28 (m, 2H), 2.81-2.78 (m, 1H), 2.59-2.58 (m, 1H), 2.23-2.22 (m, 1H) ppm;  $^{13}$ C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  195.8, 138.6. 138.5, 138.2, 134.1, 133.8, 132.0, 130.0, 129.6<sub>0</sub>, 129.5<sub>6</sub>, 128.6, 128.5, 128.3, 128.0, 127.0, 49.7, 48.5, 45.8 ppm; IR (Neat): 2921, 1633, 1588, 1445, 1356, 1283, 1162 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>24</sub>H<sub>22</sub>NO<sub>4</sub>S [M+H]<sup>+</sup>: m/z 420.1264. Found: 420.1265.

#### (E)-N-(3-(4-chlorophenyl)-3-oxo-2-phenylprop-1-en-1-yl)-N-(oxiran-2-

ylmethyl)benzenesulfonamide (3ab). Following the general procedure, the reaction of 1a (64.0



mg, 0.30 mmol) with **2b** (55.4 mg, 0.20 mmol),  $K_2CO_3$  (55.2 mg, 0.40 mmol), after column chromatography (EtOAc:hexane = 1:9) afforded **3ab** as a white solid. Yield 78 mg (86%). Mp 105-106 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$ 

<sup>Cl</sup> 7.83-7.82 (m, 2H), 7.72-7.69 (m, 1H), 7.63-7.59 (m, 4H), 7.52 (s, 1H), 7.39-7.37 (m, 2H), 7.31-7.27 (m, 3H), 7.00-6.98 (m, 2H), 3.36-3.24 (m, 2H), 2.78-2.75 (m, 1H), 2.56 (dd → t, J = 4.5 Hz, 1H), 2.20-2.18 (dd, J = 4.5, 2.5 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 194.4, 138.5. 138.4, 138.2, 136.9, 133.9, 131.1, 130.0, 129.6, 128.7, 128.6, 127.6, 127.4, 49.8, 48.5, 45.7 ppm; IR (Neat): 3076, 1638, 1588, 1445, 1356, 1274, 1163 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>24</sub>H<sub>21</sub>CINO<sub>4</sub>S [M+H]<sup>+</sup>: m/z 454.0874. Found: 454.0877. (*E*)-4-methyl-N-(oxiran-2-ylmethyl)-N-(3-oxo-2,3-diphenylprop-1-en-1-yl)benzenesulfonamide (3ba). Following the general procedure, the reaction of 1b (68.2 mg, 0.30 mmol) with 2a (48.5



mg, 0.20 mmol),  $K_2CO_3$  (55.2 mg, 0.40 mmol), after column chromatography (EtOAc:hexane = 1:9) afforded **3ba** as a white solid. Yield 81 mg (87%). Mp 88-89 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.71-7.69 (m, 4H), 7.56-7.53 (m, 2H), 7.46-7.43 (m, 2H), 7.39 (d, *J* = 8.5 Hz,

2H), 7.33-7.31 (m, 3H), 7.08-7.07 (m, 2H), 3.33-3.32 (m, 2H), 2.79-2.76 (m, 1H), 2.58 (dd $\rightarrow$ t, *J* = 4.0 Hz, 1H), 2.50 (s, 3H), 2.22-2.21 (m, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):  $\delta$  195.9, 145.0. 139.0, 138.7, 135.2, 134.2, 132.0, 130.2, 129.6, 128.6, 128.5, 128.3, 127.5, 127.3, 49.7, 48.4, 45.9, 21.7 ppm; IR (Neat): 2992, 1641, 1592, 1414, 1348, 1274, 1168 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>25</sub>H<sub>24</sub>NO<sub>4</sub>S [M+H]<sup>+</sup>: *m/z* 434.1421. Found: 434.1425.

(E)-N-(3-(4-chlorophenyl)-3-oxo-2-phenylprop-1-en-1-yl)-4-methyl-N-(oxiran-2-

ylmethyl)benzenesulfonamide (3bb). Following the general procedure, the reaction of 1b (68.2



mg, 0.30 mmol) with **2b** (55.4 mg, 0.20 mmol),  $K_2CO_3$  (55.2 mg, 0.40 mmol), after column chromatography (EtOAc:hexane = 1:9) afforded **3bb** as a white solid. Yield 78 mg (86%). Mp 119-120 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.73-7.71 (m, 2H), 7.65-7.62 (m, 2H), 7.55 (s, 1H), 7.41-

7.39 (m, 4H), 7.34-7.31 (m, 3H), 7.07-7.05 (m, 2H), 3.38-3.29 (m, 2H), 2.79-2.76 (m, 1H), 2.58-2.56 (m, 1H), 2.51 (s, 3H), 2.21-2.20 (m, 1H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  194.5, 145.1. 138.9, 138.2, 137.0, 135.2, 134.0, 131.0, 130.2, 130.1, 128.7, 128.6, 127.4, 127.0, 49.7, 48.3, 45.8, 21.7 ppm; IR (Neat): 2922, 1650, 1553, 1491, 1360, 1243, 1164 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>25</sub>H<sub>23</sub>ClNO<sub>4</sub>S [M+H]<sup>+</sup>: *m/z* 468.1031. Found: 468.1036.

# (E)-4-methoxy-N-(oxiran-2-ylmethyl)-N-(3-oxo-2,3-diphenylprop-1-en-1-

yl)benzenesulfonamide (3ca).<sup>7</sup> Following the general procedure, the reaction of 1c (73.0 mg,



0.30 mmol) with **2a** (48.5 mg, 0.20 mmol),  $K_2CO_3$  (55.2 mg, 0.40 mmol), after column chromatography (EtOAc:hexane = 1:9) afforded **3ca** as a white solid. Yield 69 mg (77%). Mp 129-130 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.75 (d, *J* = 9.0 Hz, 2H), 7.70-7.68 (m, 2H), 7.57-7.53

(m, 2H), 7.45-7.42 (m, 2H), 7.33-7.32 (m, 3H), 7.11-7.09 (m, 2H), 7.04 (d, J = 9.0 Hz, 2H), 3.93 (s, 3H), 3.34-3.33 (m, 2H), 2.79-2.76 (m, 1H), 2.58 (dd  $\rightarrow$  t, J = 4.5 Hz, 1H), 2.22-2.20 (m, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 195.9, 163.9, 139.3. 138.7, 134.3, 131.9, 130.2, 129.7, 129.6, 128.6, 128.4, 128.3, 126.9, 114.7, 55.8, 49.7, 48.3, 45.9 ppm; IR (Neat): 2916, 1636, 1591, 1494, 1348, 1260, 1150 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>25</sub>H<sub>24</sub>NO<sub>5</sub>S [M+H]<sup>+</sup>: m/z 450.1370. Found: 450.1367.

## (E)-N-(3-(4-chlorophenyl)-3-oxo-2-phenylprop-1-en-1-yl)-4-methoxy-N-(oxiran-2-

ylmethyl)benzenesulfonamide (3cb). Following the general procedure, the reaction of 1c (73.0



mg, 0.30 mmol) with **2b** (55.4 mg, 0.20 mmol),  $K_2CO_3$  (55.2 mg, 0.40 mmol), after column chromatography (EtOAc:hexane = 1:9) afforded **3cb** as a white solid. Yield 82 mg (88%). Mp 87-88 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.78-7.75 (m, 2H), 7.64-7.61 (m, 2H), 7.56 (s, 1H),

7.40-7.38 (m, 2H), 7.33-7.32 (m, 3H), 7.09-7.04 (m, 4H), 3.94 (s, 3H), 3.39-3.28 (m, 2H), 2.78-2.75 (m, 1H), 2.57 (dd  $\rightarrow$  t, J = 5.0 Hz, 1H), 2.20-2.19 (m, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 194.6, 163.9, 139.3. 138.2, 137.1, 134.1, 131.0, 130.2, 129.7, 129.4, 128.7, 128.6, 126.4, 114.7, 55.9, 49.7, 48.2, 45.8 ppm; IR (Neat): 2925, 1650, 1593, 1552, 1495, 1358, 1244, 1163 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>25</sub>H<sub>23</sub>ClNO<sub>5</sub>S [M+H]<sup>+</sup>: m/z 484.0980. Found: 484.0977.

(*E*)-4-chloro-N-(oxiran-2-ylmethyl)-N-(3-oxo-2,3-diphenylprop-1-en-1-yl)benzenesulfonamide (3da). Following the general procedure, the reaction of 1d (74.3 mg, 0.30 mmol) with 2a (48.5



mg, 0.20 mmol),  $K_2CO_3$  (55.2 mg, 0.40 mmol), after column chromatography (EtOAc:hexane = 1:9) afforded **3da** as a white solid. Yield 68 mg (75%). Mp 102-103 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.76-7.73 (m, 2H), 7.69-7.67 (m, 2H), 7.56-7.52 (m, 3H), 7.44-7.41 (m, 3H),

7.32-7.30 (m, 3H), 7.09-7.05 (m, 2H), 3.39-3.25 (m, 2H), 2.78-2.75 (m, 1H), 2.58 (dd  $\rightarrow$  t, J = 4.5 Hz, 1H), 2.22-2.21 (m, 1H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 195.6, 140.6, 138.4. 137.8, 136.6, 134.0, 132.1, 130.0, 129.8, 129.6, 128.9, 128.7, 128.6, 128.5, 128.3 49.6, 48.7, 45.7 ppm; IR (Neat): 3062, 1652, 1559, 1443, 1364, 1252, 1165 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{24}H_{21}CINO_{4}S [M+H]^{+}$ : m/z 454.0874. Found: 454.0873.

# $(E) \hbox{-} 4-chloro-N-(3-(4-chlorophenyl)-3-oxo-2-phenylprop-1-en-1-yl)-N-(oxiran-2-phenylprop-1-en-1--ylprop-1-en-1-en-1-ylprop-1-en-1-en-1-ylprop-1-en-1-en-1-yl$

ylmethyl)benzenesulfonamide (3db). Following the general procedure, the reaction of 1d (74.3



mg, 0.30 mmol) with **2b** (55.4 mg, 0.20 mmol), K<sub>2</sub>CO<sub>3</sub> (55.2 mg, 0.40 mmol), after column chromatography (EtOAc:hexane = 1:9) afforded **3db** as a white solid. Yield 83 mg (85%). Mp 130-131 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.80-7.78 (m, 2H), 7.66-7.63 (m, 2H), 7.60-7.57 (m,

2H), 7.47 (s, 1H), 7.42-7.39 (m, 2H), 7.35-7.32 (m, 3H), 7.08-7.05 (m, 2H), 3.41 (dd, J = 15.0, 4.0 Hz, 1H), 3.28 (dd, J = 16.0, 6.0 Hz, 1H), 2.80-2.77 (m, 1H), 2.60-2.59 (m, 1H), 2.23 (dd, J = 4.5, 2.5 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 194.3, 140.7, 138.5. 137.9, 136.7, 136.6, 133.9, 131.1, 130.0, 129.9, 128.9, 128.8, 128.7, 128.1, 49.7, 48.7, 45.7 ppm; IR (Neat): 3073, 1650, 1554, 1479, 1365, 1244, 1167 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>24</sub>H<sub>20</sub>Cl<sub>2</sub>NO<sub>4</sub>S [M+H]<sup>+</sup>: m/z 488.0485. Found: 488.0486.

#### (E)-2-nitro-N-(oxiran-2-vlmethyl)-N-(3-oxo-2,3-diphenylprop-1-en-1-vl)benzenesulfonamide

(3ea). Following the general procedure, the reaction of 1e (78.4 mg, 0.30 mmol) with 2a (48.5



0.20 mmol),  $K_2CO_3$  (55.2 mg, 0.40 mmol), after column mg. chromatography (EtOAc:hexane = 1:9) afforded **3ea** as a semisolid. Yield 77 mg (83%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.04 (d, J = 7.0 Hz, 1H), 7.84-

7.78 (m, 2H), 7.77-7.73 (m, 3H), 7.55-7.52 (m, 1H), 7.48 (s, 1H), 7.44-7.41

(m, 2H), 7.32-7.31 (m, 3H), 7.14-7.12 (m, 2H), 3.56 (dd, J = 16.0, 3.5 Hz, 1H), 3.34 (dd, J = 16.0, 3.5 Hz, 1H), 3.54 (dd, J = 16.0, 3.5 Hz, 1H), 3.54 (dd, J = 16.0, 3.5 16.0, 5.5 Hz, 1H), 2.92-2.89 (m, 1H), 2.63 (dd $\rightarrow$ t, J = 4.0 Hz, 1H), 2.33-2.32 (m, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 195.8, 147.8, 138.3. 137.1, 134.9, 133.9, 132.3, 132.2, 131.8, 131.6, 129.9, 129.7, 129.4, 128.7, 128.4, 124.9, 50.0, 48.9, 45.6 ppm; IR (Neat): 3020, 1648, 1539, 1442, 1363, 1275, 1166 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{24}H_{21}N_2O_6S$  [M+H]<sup>+</sup>: m/z 465.1115. Found: 465.1116.

## (E)-N-(3-(4-chlorophenyl)-3-oxo-2-phenylprop-1-en-1-yl)-2-nitro-N-(oxiran-2-

*ylmethyl)benzenesulfonamide* (3eb). Following the general procedure, the reaction of 1e (78.4



mg, 0.30 mmol) with 2b (55.4 mg, 0.20 mmol), K<sub>2</sub>CO<sub>3</sub> (55.2 mg, 0.40 mmol), after column chromatography (EtOAc:hexane = 1:9) afforded **3eb** as a white solid. Yield 87 mg (87%). Mp 146-147 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.08-8.06 (m, 1H), 7.85-7.79 (m, 2H), 7.78-7.76 (m, 1H), 7.73-7.70 (m, 2H), 7.50 (s, 1H), 7.41-7.38 (m, 2H), 7.33-7.30 (m, 3H), 7.14-7.10 (m, 2H), 3.56 (dd, J = 16.0, 3.5 Hz, 1H), 3.32 (dd, J = 16.0, 6.0 Hz, 1H), 2.90-2.87 (m, 1H), 2.62-2.60 (m, 1H), 2.31-

2.29 (m, 1H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 194.4, 147.8, 138.6. 137.1, 136.6, 135.0, 133.8, 132.3, 131.9, 131.5, 131.2, 129.9, 128.8, 128.7<sub>3</sub>, 128.6<sub>7</sub>, 124.9, 49.9, 48.9, 45.5 ppm; IR (Neat): 3020, 1652, 1539, 1355, 1264, 1164 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>24</sub>H<sub>20</sub>ClN<sub>2</sub>O<sub>6</sub>S [M+H]<sup>+</sup>: *m/z* 499.0725. Found: 499.0724.

#### (E)-N-(oxiran-2-ylmethyl)-N-(3-oxo-2,3-diphenylprop-1-en-1-yl)thiophene-2-sulfonamide

(3fa). Following the general procedure, the reaction of 1f (65.8 mg, 0.30 mmol) with 2a (48.5



mg, 0.20 mmol), K<sub>2</sub>CO<sub>3</sub> (55.2 mg, 0.40 mmol), after column chromatography (EtOAc:hexane = 1:9) afforded **3fa** as a white solid. Yield 64 mg (75%). Mp 134-135 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.75-7.74 (m, 3H), 7.67-7.66 (m, 1H), 7.56-7.53 (m, 1H), 7.46-7.43 (m, 3H), 7.35-7.32 (m, 3H), 7.21-7.19 (m,

1H), 7.12-7.10 (m, 2H), 3.38-3.28 (m, 2H), 2.85-2.82 (m, 1H), 2.62 (dd  $\rightarrow$  t, J = 4.5 Hz, 1H), 2.26-2.25 (m, 1H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 195.6, 138.2<sub>9</sub>, 138.2<sub>7</sub>. 137.6, 134.0, 133.5<sub>4</sub>, 133.4<sub>8</sub>, 132.2, 129.9, 129.7, 129.4, 128.7, 128.6, 128.3, 127.9, 49.6, 49.0, 45.9 ppm; IR (Neat): 3073, 1637, 1590, 1443, 1361, 1282, 1161 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>22</sub>H<sub>20</sub>NO<sub>4</sub>S<sub>2</sub> [M+H]<sup>+</sup>: m/z 426.0828. Found: 426.0825.

# (E) - N - (3 - (4 - chlorophenyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) thiophene - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 - en - 1 - yl) - N - (oxiran - 2 - ylmethyl) - 3 - oxo - 2 - phenyl prop - 1 -

sulfonamide (3fb). Following the general procedure, the reaction of 1f (65.8 mg, 0.30 mmol)



with **2b** (55.4 mg, 0.20 mmol), K<sub>2</sub>CO<sub>3</sub> (55.2 mg, 0.40 mmol), after column chromatography (EtOAc:hexane = 1:9) afforded **3fb** as a white solid. Yield 79 mg (86%). Mp 111-112 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.75-7.73 (m, 1H), 7.68-7.65 (m, 3H), 7.44 (s, 1H), 7.40-7.39 (m, 2H), 7.33-7.31 (m, 3H),

7.20-7.18 (m, 1H), 7.09-7.05 (m, 2H), 3.37-3.25 (m, 2H), 2.82-2.79 (m, 1H), 2.60-2.58 (m, 1H), 2.23-2.21 (m, 1H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 195.7, 138.3, 138.2. 137.7, 134.0, 133.6, 133.5, 132.2, 131.1, 129.9, 129.4, 128.7, 128.6, 128.3, 127.9, 49.7, 49.0, 45.9 ppm; IR (Neat):

3093, 1638, 1590, 1362, 1283, 1161 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>22</sub>H<sub>19</sub>ClNO<sub>4</sub>S<sub>2</sub> [M+H]<sup>+</sup>: *m/z* 460.0439. Found: 460.0434.

# $(E) \text{-} N \text{-} (oxiran \text{-} 2 \text{-} ylmethyl) \text{-} N \text{-} (3 \text{-} oxo \text{-} 2, 3 \text{-} diphenyl prop \text{-} 1 \text{-} en \text{-} 1 \text{-} yl) naph thal en e \text{-} 2 \text{-} sulfon a mide a subscript{a} a subscript{b} a subscript{b$

(3ga). Following the general procedure, the reaction of 1g (79.0 mg, 0.30 mmol) with 2a (48.5



mg, 0.20 mmol),  $K_2CO_3$  (55.2 mg, 0.40 mmol), after column chromatography (EtOAc:hexane = 1:9) afforded **3ga** as a white solid. Yield 71 mg (76%). Mp 123-124 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.38-8.37 (m, 1H), 8.04 (d, *J* = 9.0 Hz, 1H), 7.98-7.96 (m, 2H), 7.77-7.64

(m, 5H), 7.60 (s, 1H), 7.52-7.49 (m, 1H), 7.39-7.135 (m, 2H), 7.29-7.27 (m, 1H), 7.26-7.23 (m, 2H), 7.06-7.03 (m, 2H), 3.41-3.33 (m, 2H), 2.80-2.77 (m, 1H), 2.55 (dd  $\rightarrow$  t, J = 4.5 Hz, 1H), 2.22-2.21 (m, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 195.8, 138.9, 138.7. 135.2, 134.9, 134.1, 132.1, 132.0, 130.1, 130.0, 129.6, 129.5, 129.4, 128.6, 128.5, 128.3, 128.1, 127.5, 122.0, 49.8, 48.5, 45.9 ppm; IR (Neat): 2996, 1641, 1590, 1443, 1351, 1274, 1167 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>28</sub>H<sub>24</sub>NO<sub>4</sub>S [M+H]<sup>+</sup>: *m/z* 470.1421. Found: 470.1419.

#### (E)-N-(3-(4-chlorophenyl)-3-oxo-2-phenylprop-1-en-1-yl)-N-(oxiran-2-ylmethyl)naphthalene-

2-sulfonamide (3gb) Following the general procedure, the reaction of 1g (79.0 mg, 0.30 mmol)



with **2b** (55.4 mg, 0.20 mmol),  $K_2CO_3$  (55.2 mg, 0.40 mmol), after column chromatography (EtOAc:hexane = 1:9) afforded **3gb** as a white solid. Yield 87 mg (86%). Mp 145-146 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.39-8.38 (m, 1H), 8.05 (d, *J* = 9.0 Hz, 1H), 7.98 (d, *J* = 9.0 Hz, 2H),

7.78-7.76 (m, 1H), 7.75-7.72 (m, 1H), 7.71-7.68 (m, 1H), 7.58-7.56 (m, 3H), 7.32-7.29 (m, 2H), 7.28-7.23 (m, 3H), 7.04-7.01 (m, 2H), 3.44-3.32 (m, 2H), 2.80-2.76 (m, 1H), 2.55 (dd  $\rightarrow$  t, J =4.5 Hz, 1H), 2.21-2.20 (m, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 194.5, 139.0, 138.2. 137.0, 135.2, 134.8, 134.0, 132.1, 131.0, 130.1, 129.7, 129.5, 128.7, 128.6, 128.2, 128.1, 127.0, 121.9, 49.7, 48.4, 45.8 ppm; IR (Neat): 3062, 1641, 1586, 1354, 1270, 1168 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{28}H_{23}CINO_4S$  [M+H]<sup>+</sup>: m/z 504.1031. Found: 504.1037.

# (E)-4-methyl-N-(3-oxo-2,3-diphenylprop-1-en-1-yl)-N-((3-phenyloxiran-2-

yl)methyl)benzenesulfonamide (3la) Following the general procedure, the reaction of 1l (91.0



mg, 0.30 mmol) with **2a** (48.5 mg, 0.20 mmol) using  $K_2CO_3$  (55.2 mg, 0.40 mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **3la** as a semi solid. Yield 83 mg (81%); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.72-7.68 (m, 4H), 7.58 (s, 1H), 7.55-7.52 (m, 1H), 7.44-7.41 (m, 2H), 7.37-7.34 (m, 5H), 7.31-7.29 (m, 2H), 7.28-7.26 (m, 1H), 7.15-7.013 (m,

2H), 7.06 (d, J = 6.5 Hz, 2H), 3.50-3.39 (m, 3H), 2.81-2.80 (m, 1H), 2.49 (s, 3H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 195.9, 145.1, 138.9. 138.7, 136.1, 135.2, 134.2, 132.0, 130.2, 129.6, 128.7, 128.5, 128.3, 127.4, 125.7, 59.7, 57.7, 48.0, 21.7 ppm; IR (Neat): 2927, 1733, 1649, 1594, 1444, 1356, 1241, 1163 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>31</sub>H<sub>28</sub>NO<sub>4</sub>S [M+H]<sup>+</sup>: m/z 510.1734. Found: 510.1735.

## 4 (b). General procedure for the synthesis of compounds 4aa-4gb:



(*i*) *Procedure:* To a solution of *N*-(oxiran-2-ylmethyl)-*N*-(3-oxo-2,3-diphenylprop-1-en-1yl)benzenesulfonamide **3aa** (83.9 mg, 0.2 mmol 1.0 equiv) in dry CHCl<sub>3</sub> (2 mL), BF<sub>3</sub><sup>·</sup>OEt<sub>2</sub> (5.0

µL, 0.04 mmol, 0.2 equiv) was added. The resulting reaction mixture was stirred for 3 h at rt (25 <sup>o</sup>C). After the completion of the reaction as monitored by TLC, DCM (10 mL) was added and the solution was washed with water (3  $\times$  10 mL), then brine solution (3  $\times$  10 mL); the aqueous layer was extracted with DCM ( $3 \times 10$  mL). The combined organic portion was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, the solvent was evaporated under the reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: hexane/ethyl acetate 9: 1) to obtain compound 4aa as a white solid. Crystallization was done from an ethyl acetate-hexane mixture (1:20). Other compounds were prepared similarly.

## *(ii) Alternative procedure:*

We could also achieve the formation of **4** by starting with 3-chloro-2,3-diphenylacrylaldehyde (0.20 mmol 1.0 equiv), K<sub>2</sub>CO<sub>3</sub> (0.40 mmol, 2.0 equiv) in dry DMF (5 mL) and epoxy benzene sulfonamide (0.30 mmol 1.5 equiv). The resulting mixture was heated for 2 h on an oil bath maintained at 80 °C. After the completion of the reaction as monitored by TLC, the solvent was removed and BF<sub>3</sub>OEt<sub>2</sub> (20 mol%) in CHCl<sub>3</sub> (2 mL) was added at 25 °C. The mixture was stirred for 3 h, without isolating the intermediate compound 3. Removal of DMF was necessary for this method.

3,4-diphenyl-9-(phenylsulfonyl)-2,6-dioxa-9-azabicyclo[3.2.2]non-3-ene (4aa). Following the general procedure, the reaction of **3aa** (83.9 mg, 0.2 mmol) with BF<sub>3</sub> OEt<sub>2</sub> (5.0 µL, 0.04 mmol)



after column chromatography (EtOAc:hexane = 1:9) afforded **4aa** as a white solid. Yield 62 mg (74%). Mp 182-183 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.90 (d, J = 7.5 Hz, 2H), 7.62-7.59 (m, 1H), 7.53-7.50 (m, 2H), 7.21-7.15 (m, 10H), 6.05 (s, 1H), 4.59-4.56 (m, 2H), 4.28 (dt, J = 12.0, 2.5 Hz, 1H), 3.79 (dd, J = 12.0, 4.0 Hz, 1H),

133.0, 130.1, 129.6, 129.1, 128.6, 128.5, 127.7, 127.7<sub>4</sub>, 126.6<sub>8</sub>, 114.5, 85.6, 72.4, 67.7, 48.6 ppm; IR (Neat): 2919, 2970, 1635, 1446, 1349, 1262, 1161 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{24}H_{22}NO_4S [M+H]^+$ : m/z 420.1264. Found: 420.1261.

**3-(4-chlorophenyl)-4-phenyl-9-(phenylsulfonyl)-2,6-dioxa-9-azabicyclo[3.2.2]non-3-ene (4ab).** Following the general procedure, the reaction of **3ab** (90.8 mg, 0.2 mmol) with BF<sub>3</sub>'OEt<sub>2</sub> (5.0



μL, 0.04 mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **4ab** as a white solid. Yield 69 mg (76%). Mp 134-135 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.90-7.89 (m, 2H), 7.62-7.59 (m, 1H), 7.53-7.50 (m, 2H), 7.25-7.18 (m, 3H), 7.16-7.08 (m, 6H), 6.03 (s, 1H), 4.59-4.53

(m, 2H), 4.27 (dt, J = 12.0, 2.5 Hz, 1H), 3.79 (dd, J = 12.0, 4.0 Hz, 1H), 3.61 (dd, J = 12.0, 3.5 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 151.9, 138.6, 138.1, 134.4, 133.8, 133.1, 130.9, 130.0, 128.7, 128.0, 127.7, 127.0, 115.0, 85.6, 72.6, 67.6, 48.5 ppm; IR (Neat): 2866, 1633, 1487, 1445, 1353, 1163 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>24</sub>H<sub>21</sub>ClNO<sub>4</sub>S [M+H]<sup>+</sup>: m/z 454.0874. Found: 454.0878.

3,4-diphenyl-9-tosyl-2,6-dioxa-9-azabicyclo[3.2.2]non-3-ene (4ba). Following the general procedure, the reaction of 3ba (86.7 mg, 0.2 mmol) with BF<sub>3</sub>·OEt<sub>2</sub> (5.0 µL, 0.04 mmol) after



column chromatography (EtOAc:hexane = 1:9) afforded **4ba** as a white solid. Yield 68 mg (78%). Mp 175-176  $^{\circ}$ C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.78 (d, *J* = 8.5 Hz, 2H), 7.29 (d, *J* = 8.5 Hz, 2H), 7.20-7.15 (m, 10H), 6.03

(s, 1H), 4.58-4.55 (m, 2H), 4.28-4.26 (m, 1H), 3.79 (dd, *J* = 12.0, 3.5 Hz, 1H), 3.60 (dd, *J* = 12.0, 2.5 Hz, 1H) 2.43 (s, 3H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 153.0, 143.8, 138.9, 135.4, 135.2, 130.1, 129.7, 129.6, 128.5, 128.5, 127.7, 126.7, 114.5, 85.6, 72.5, 67.6, 48.5, 21.6 ppm; IR

(Neat): 2926, 2862, 1634, 1446, 1341, 1316, 1252, 1159 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{24}H_{24}NO_4S [M+H]^+$ : m/z 434.1421. Found: 434.1420.

**3-(4-chlorophenyl)-4-phenyl-9-tosyl-2,6-dioxa-9-azabicyclo[3.2.2]non-3-ene** (**4bb**). Following the general procedure, the reaction of **3bb** (93.6 mg, 0.2 mmol) with BF<sub>3</sub>·OEt<sub>2</sub> (5.0 μL, 0.04



mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **4bb** as a white solid. Yield 71 mg (76%). Mp 172-173 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.77 (d, *J* = 8.5 Hz, 2H), 7.30 (d, *J* = 8.5 Hz, 2H), 7.24-7.19 (m, 3H), 716-7.14 (m, 2H), 7.13-7.08 (m, 4H), 6.01 (s, 1H),

4.58-4.52 (m, 2H), 4.26 (dt, J = 12.5, 2.5 Hz, 1H), 3.79 (dd, J = 12.0, 4.0 Hz, 1H), 3.59 (dd, J = 12.5, 3.5 Hz, 1H) 2.43 (s, 3H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 151.9, 143.9, 138.6, 135.1, 134.4, 133.8, 130.9, 130.0, 129.8, 128.7, 128.0, 127.7, 127.0, 115.0, 85.5, 72.6, 67.6, 48.5, 21.6 ppm; IR (Neat): 2921, 2868, 1629, 1487, 1351, 1175, 1161 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{24}H_{23}CINO_4S$  [M+H]<sup>+</sup>: m/z 468.1031. Found: 468.1034.

*9-((4-methoxyphenyl)sulfonyl)-3,4-diphenyl-2,6-dioxa-9-azabicyclo[3.2.2]non-3-ene* (4ca). Following the general procedure, the reaction of **3ca** (89.9 mg, 0.2 mmol) with BF<sub>3</sub>·OEt<sub>2</sub> (5.0 μL,



0.04 mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **4ca** as a white solid. Yield 69 mg (77%). Mp 146-147  $^{\circ}$ C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.83 (d, *J* = 8.5 Hz, 2H), 7.19-7.16 (m, 10H), 6.96 (d, *J* = 8.5 Hz, 2H), 6.03 (s, 1H), 4.58-4.55 (m, 2H), 4.26 (d,

J = 12.5 Hz, 1H), 387 (s, 3H), 3.79 (dd, J = 12.0, 3.5 Hz, 1H), 3.60 (dd, J = 12.0, 2.5 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 163.2, 153.0, 139.0, 135.4, 130.1, 129.9, 129.8, 129.6, 128.5<sub>3</sub>, 128.4<sub>7</sub>, 127.7, 126.7, 114.5, 114.3, 85.6, 72.5, 67.7, 55.6, 48.5 ppm; IR (Neat): 1634, 1601, 1499, 1345, 1262, 1175, 1160 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{24}H_{24}NO_5S$  [M+H]<sup>+</sup>: m/z 450.1370. Found: 450.1373.

# 3-(4-chlorophenyl)-9-((4-methoxyphenyl)sulfonyl)-4-phenyl-2,6-dioxa-9-azabicyclo[3.2.2]non-3-ene (4cb). Following the general procedure, the reaction of 3cb (96.8 mg, 0.2 mmol) with



BF<sub>3</sub>·OEt<sub>2</sub> (5.0  $\mu$ L, 0.04 mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **4cb** as a white solid. Yield 72 mg (74%). Mp 165-166 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.83-7.81 (m, 2H), 7.24-7.19 (m, 3H), 7.16-7.08 (m, 6H), 6.97-6.95 (m, 2H), 6.01 (s,

1H), 4.58-4.53 (m, 2H), 4.23 (d, J = 12.5 Hz, 1H), 388 (s, 3H), 3.81-3.78 (m, 1H), 3.58 (dd, J = 12.0, 3.0 Hz, 1H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 163.2, 151.8, 138.6, 134.3, 133.9, 130.8, 130.0, 129.8, 129.7, 128.6, 127.9, 126.9, 115.0, 114.2, 85.5, 72.6, 67.6, 55.6, 48.5 ppm; IR (Neat): 2922, 1630, 1594, 1494, 1349, 1310, 1224, 1177 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>24</sub>H<sub>23</sub>CINO<sub>5</sub>S [M+H]<sup>+</sup>: m/z 484.0980. Found: 484.0980.

# 9-((4-chlorophenyl)sulfonyl)-3,4-diphenyl-2,6-dioxa-9-azabicyclo[3.2.2]non-3-ene (4da).

Following the general procedure, the reaction of 3da (90.8 mg, 0.2 mmol) with BF<sub>3</sub>·OEt<sub>2</sub> (5.0



μL, 0.04 mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **4db** as a white solid. Yield 64 mg (70%). Mp 145-146 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.82-7.80 (m, 2H), 7.47-7.44 (m, 2H), 7.22-7.16 (m, 4H), 7.16-7.12 (m, 6H), 6.02 (s, 1H), 4.62-4.58 (m, 2H), 4.27

(dt, J = 12.5 Hz, 3.0 Hz, 1H), 3.86 (dd, J = 12.0, 4.0 Hz, 1H), 3.59 (dd, J = 12.0, 3.5 Hz, 1H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 153.2, 139.5, 138.8, 136.8, 135.2, 130.0, 129.5, 129.4, 129.0, 128.6, 128.5, 127.7, 126.8, 114.2, 85.7, 72.4, 67.7, 48.6 ppm; IR (Neat): 2868, 1633, 1446, 1353, 1258, 1163, 1088 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{24}H_{21}CINO_4S$  [M+H]<sup>+</sup>: m/z 454.0874. Found: 454.0870.

# 3-(4-chlorophenyl)-9-((4-chlorophenyl)sulfonyl)-4-phenyl-2,6-dioxa-9-azabicyclo[3.2.2]non-3ene (4db). Following the general procedure, the reaction of 3db (97.8 mg, 0.2 mmol) with



BF<sub>3</sub>·OEt<sub>2</sub> (5.0  $\mu$ L, 0.04 mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **4db** as a white solid. Yield 67 mg (68%). Mp 202-203 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.82-7.79 (m, 2H), 7.48-7.45 (m, 2H), 7.25-7.18 (m, 3H), 7.14-7.11 (m, 4H), 7.09-

7.07 (m, 2H), 6.00 (s, 1H), 4.62-4.56 (m, 2H), 4.26 (dt, J = 12.5, 2.5 Hz, 1H), 3.86 (dd, J = 12.0, 4.0 Hz, 1H), 3.58 (dd, J = 12.0, 3.5 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 152.0, 139.6, 138.4, 136.6, 134.5, 133.6, 130.8, 129.9, 129.4, 129.0, 128.7, 128.0, 127.0, 114.7, 85.6, 72.5, 67.6, 48.6 ppm; IR (Neat): 2924, 1628, 1485, 1382, 1224, 1165, 1089 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>24</sub>H<sub>20</sub>Cl<sub>2</sub>NO<sub>4</sub>S [M+H]<sup>+</sup>: m/z 488.0485. Found: 488.0486.

# 9-((2-nitrophenyl)sulfonyl)-3,4-diphenyl-2,6-dioxa-9-azabicyclo[3.2.2]non-3-ene (4ea).

Following the general procedure, the reaction of **3ea** (93.1 mg, 0.2 mmol) with BF<sub>3</sub> OEt<sub>2</sub> (5.0 µL,



0.04 mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **4ea** as a white solid. Yield 60 mg (64%). Mp 160-161 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.97 (d, *J* = 8.0 Hz, 1H), 7.69-7.63 (m, 2H), 7.58-7.55 (m, 1H), 7.22-7.19 (m, 3H), 7.17-7.13 (m, 5H), 7.11-7.09 (m, 2H), 6.04 (s, 1H),

4.74-4.67 (m, 2H), 4.27 (dt, *J* = 12.5, 2.0 Hz, 1H), 4.12 (dd, *J* = 12.0, 3.5 Hz, 1H), 3.99 (dd, *J* = 12.0, 3.5 Hz, 1H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 153.5, 148.5, 138.6, 135.2, 133.7, 132.3, 131.8, 130.4, 130.1, 129.6, 128.7, 128.5, 127.7, 126.7, 124.2, 114.2, 85.7, 72.8, 67.9, 48.8 ppm;

IR (Neat): 2951, 1538, 1442, 1359, 1269, 1166 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{24}H_{21}N_2O_6S$ [M+H]<sup>+</sup>: m/z 465.1115. Found: 465.1118.

# $\label{eq:constraint} 3-(4-chlorophenyl)-9-((2-nitrophenyl)sulfonyl)-4-phenyl-2, 6-dioxa-9-azabicyclo [3.2.2] non-3-azabicyclo [3.2.2] non-3-aza$

ene (4eb). Following the general procedure, the reaction of 3eb (99.8 mg, 0.2 mmol) with



BF<sub>3</sub>·OEt<sub>2</sub> (5.0 μL, 0.04 mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **4eb** as a white solid. Yield 63 mg (63%). Mp 89-90 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.95 (d, J = 8.0 Hz, 1H), 7.70-7.63 (m, 2H), 7.59-7.56 (m, 1H), 7.16-7.08 (m, 9H), 6.02 (s, 1H),

4.74 (s, 1H), 4.66 (d, J = 12.0 Hz, 2H), 4.35 (d, J = 12.0 Hz, 1H), 4.15 (dd, J = 12.0, 3.5 Hz, 1H), 3.97 (dd, J = 12.0, 2.5 Hz, 1H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 152.3, 148.5, 138.2, 134.5, 133.8, 133.7, 132.2, 131.8, 130.9, 130.4, 130.0, 128.7, 128.0, 127.0, 124.2, 114.7, 85.6, 72.9, 67.8, 48.7 ppm; IR (Neat): 2921, 2852, 1629, 1542, 1456, 1356, 1260, 1166 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>24</sub>H<sub>20</sub>ClN<sub>2</sub>O<sub>6</sub>S [M+H]<sup>+</sup>: m/z 499.0725. Found: 499.0724.

# 3,4-diphenyl-9-(thiophen-2-ylsulfonyl)-2,6-dioxa-9-azabicyclo[3.2.2]non-3-ene (4fa).

Following the general procedure, the reaction of **3fa** (85.1 mg, 0.2 mmol) with BF<sub>3</sub> OEt<sub>2</sub> (5.0 µL,



0.04 mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **4fa** as a white solid. Yield 61 mg (72%). Mp 194-195 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.67-7.61 (m, 2H), 7.20-7.16 (m, 10H), 7.12-7.10 (m, 1H), 6.02 (s, 1H), 4.64-4.61 (m, 2H), 4.35 (dt, *J* = 12.0, 2.5 Hz, 1H), 3.90 (dd, *J* =

12.5, 4.5 Hz, 1H), 3.69 (dd, J = 12.0, 3.0 Hz, 1H) ppm; <sup>13</sup>C{<sup>1</sup>H} NMR (125 MHz, CDCl<sub>3</sub>): 153.3, 138.8, 138.4, 135.3, 132.8, 132.4, 130.1, 129.6, 128.6, 128.5, 127.7, 127.5, 126.7, 114.1, 85.8, 72.3, 67.6, 48.8 ppm; IR (Neat): 2922, 2871, 1632, 1444, 1351, 1265, 1157 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>22</sub>H<sub>20</sub>NO<sub>4</sub>S<sub>2</sub> [M+H]<sup>+</sup>: m/z 426.0828. Found: 426.0830. **3-(4-chlorophenyl)-4-phenyl-9-(thiophen-2-ylsulfonyl)-2,6-dioxa-9-azabicyclo[3.2.2]non-3-ene** (**4fb**). Following the general procedure, the reaction of **3fb** (92.0 mg, 0.2 mmol) with BF<sub>3</sub>·OEt<sub>2</sub>



(5.0 µL, 0.04 mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **4fb** as a white solid. Yield 67 mg (73%). Mp 145-146 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.63 (d, *J* = 3.0 Hz, 1H), 7.60 (d, *J* = 4.5 Hz, 1H), 7.22-7.17 (m, 3H), 7.14-7.06 (m, 7H), 5.97 (s, 1H), 4.62-4.56 (m, 2H), 4.31

(d, J = 12.0 Hz, 1H), 3.88 (dd, J = 12.0, 4.0 Hz, 1H), 3.66 (dd, J = 12.0, 2.0 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 152.1, 138.5, 138.3, 134.5, 133.7, 132.8, 132.5, 130.9, 130.0, 128.7, 128.0, 127.6, 127.0, 114.6, 85.7, 72.5, 67.6, 48.8 ppm; IR (Neat): 2928, 1635, 1489, 1350, 1261, 1224, 1158 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>22</sub>H<sub>19</sub>ClNO<sub>4</sub>S<sub>2</sub> [M+H]<sup>+</sup>: m/z 460.0439. Found: 460.0440.

# 9-(naphthalen-2-ylsulfonyl)-3,4-diphenyl-2,6-dioxa-9-azabicyclo[3.2.2]non-3-ene (4ga).

Following the general procedure, the reaction of 3ga (93.9 mg, 0.2 mmol) with BF<sub>3</sub>·OEt<sub>2</sub> (5.0



μL, 0.04 mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **4ga** as a white solid. Yield 66 mg (70%). Mp 197-198 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.44 (s, 1H), 7.94-7.88 (m, 3H), 7.85-7.83 (m, 1H), 7.66-7.59 (m, 2H), 7.17-7.09 (m, 10H), 6.12 (s, 1H), 4.55-4.52

(m, 2H), 4.30 (dt, J = 12.0, 2.5 Hz, 1H), 3.76 (dd, J = 12.0, 4.0 Hz, 1H), 3.65 (dd, J = 12.0, 3.0 Hz, 1H) ppm; <sup>13</sup>C{<sup>1</sup>H} NMR (125 MHz, CDCl<sub>3</sub>): 153.1, 138.9, 135.3, 135.1, 135.0, 132.1, 130.0, 129.5<sub>3</sub>, 129.4<sub>7</sub>, 129.3, 129.2, 128.9, 128.5<sub>2</sub>, 128.4<sub>5</sub>, 127.9, 127.7, 127.5, 126.7, 122.7, 114.5, 85.6, 72.4, 67.6, 48.6 ppm; IR (Neat): 2926, 2850, 1633, 1344, 1318, 1256, 1176 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>28</sub>H<sub>24</sub>NO<sub>4</sub>S [M+H]<sup>+</sup>: m/z 470.1421. Found: 470.1422.

3-(4-chlorophenyl)-9-(naphthalen-2-ylsulfonyl)-4-phenyl-2,6-dioxa-9-azabicyclo[3.2.2]non-3-

ene (4gb). Following the general procedure, the reaction of 3gb (100.8 mg, 0.2 mmol) with



BF<sub>3</sub>·OEt<sub>2</sub> (5.0 µL, 0.04 mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **4gb** as a white solid. Yield 74 mg (73%). Mp 164-165 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.46-8.46 (m, 1H), 7.97-7.91 (m, 3H), 7.85 (dd,  $J_1$  = 8.5 Hz,  $J_2$  = 2.0 Hz, 1H), 7.69-

7.66 (m, 1H), 7.65-7.61 (m, 1H), 7.23-7.18 (m, 3H), 7.17-7.13 (m, 2H), 7.11-7.09 (m, 2H), 7.08-7.05 (m, 2H), 6.12 (s, 1H), 4.59-4.51 (m, 2H), 4.32 (dt, J = 12.0, 2.5 Hz, 1H), 3.81 (dd, J = 12.0, 4.0 Hz, 1H), 3.66 (dd, J = 12.5, 3.5 Hz, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 151.9, 138.6, 135.0, 134.9<sub>6</sub>, 134.4, 133.8, 132.1, 130.9, 130.0, 129.5, 129.4, 129.3, 129.0, 128.7, 128.0, 127.6, 127.0, 122.7, 115.0, 85.6, 72.6, 67.6, 48.6 ppm; IR (Neat): 2855, 1635, 1490, 1344, 1318, 1255, 1160 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>28</sub>H<sub>23</sub>ClNO<sub>4</sub>S [M+H]<sup>+</sup>: m/z 504.1031. Found: 504.1030.

4 (c). General procedure for the synthesis of tetrazoles 5aa-5gb:



(*i*) To a solution of N-(oxiran-2-ylmethyl)-N-(3-oxo-2,3-diphenylprop-1-en-1yl)benzenesulfonamide **3aa** (83.9 mg, 0.2 mmol 1.0 equiv) in dry CHCl<sub>3</sub> (2 mL), BF<sub>3</sub>·OEt<sub>2</sub> (5.0  $\mu$ L, 0.04 mmol, 0.2 equiv) and TMSN<sub>3</sub> (52.6  $\mu$ L, 0.40 mmol, 2.0 equiv) were added. The resulting mixture was stirred for 3 h at rt (25 °C). After the completion of the reaction (TLC), DCM (10 mL) was added, the solution was washed with water (3 × 10 mL) and then with brine solution (3  $\times$  10 mL); the aqueous layer was extracted with DCM (3  $\times$  10 mL). The combined organic portion was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, the solvent was evaporated under the reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: hexane/ethyl acetate 3: 2) to obtain compound **5aa** .as a white solid.

#### (ii) Alternative procedure:

We could also achieve the formation of **5** by starting with 3-chloro-2,3-diphenylacrylaldehyde (0.20 mmol 1.0 equiv),  $K_2CO_3$  (0.40 mmol, 2.0 equiv) in dry DMF (5 mL) and epoxy benzene sulfonamide (0.30 mmol 1.5 equiv). The resulting reaction mixture was heated for 2 h on an oil bath maintained at 80 °C. After the completion of the reaction as monitored by TLC, the solvent was removed. To this mixture BF<sub>3</sub>·OEt<sub>2</sub> (20 mol%) and TMSN<sub>3</sub> (2.0 equiv) in CHCl<sub>3</sub> (2 mL) were added at 25 °C. The contents were stirred for 3 h, without isolating the intermediate compound **3**. Work-up was similar to (i) above. Removal of DMF was necessary for this method.

#### (E)-N-(2,3-dihydroxypropyl)-N-(2-phenyl-2-(1-phenyl-1H-tetrazol-5-

yl)vinyl)benzenesulfonamide (5aa). Following the general procedure, the reaction of 3aa (83.9

125.2, 115.9, 68.6, 63.4, 50.0, ppm; IR (Neat): 3381, 1608, 1495, 1449, 1358, 1180,1166, cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{24}H_{24}N_5O_4S [M+H]^+$ : m/z 478.1544. Found: 478.1546.

#### (E)-N-(2,3-dihydroxypropyl)-4-methyl-N-(2-phenyl-2-(1-phenyl-1H-tetrazol-5-

yl)vinyl)benzenesulfonamide (5ba). Following the general procedure, the reaction of 3ba (98.3

<sup>H0</sup> <sup>H0</sup> <sup>H0</sup> <sup>H0</sup> <sup>H0</sup> <sup>H0</sup> <sup>H0</sup> <sup>H0</sup> <sup>H1</sup> <sup>H1</sup>

#### (E)-N-(2-(1-(4-chlorophenyl)-1H-tetrazol-5-yl)-2-phenylvinyl)-N-(2,3-dihydroxypropyl)-4-

methylbenzenesulfonamide (5bb). Following the general procedure, the reaction of 3bb (93.6



mg, 0.2 mmol), BF<sub>3</sub>·OEt<sub>2</sub> (5.0 µL, 0.04 mmol) and TMSN<sub>3</sub> (52.6 µL, 0.40 mmol) after column chromatography (EtOAc:hexane = 2:3) afforded **5bb** as a white solid. Yield 88 mg (84%). Mp 123-124 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.66 (d, *J* = 8.5 Hz, 2H), 7.34 (d, *J* = 8.0 Hz, 2H), 7.21 (s, 1H), 7.18-7.15 (m, 2H), 7.12-7.09 (m, 1H), 7.04-7.01 (m, 4H), 6.70-6.68 (m, 2H),

3.49-3.47 (m, 1H), 3.23-3.15 (m, 2H), 3.03-2.95 (m, 2H), 2.57 (bs, 1H), 2.44 (s, 3H), 1.97 (bs, 1H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 154.5, 144.8 136.0, 135.0, 132.7, 132.4, 132.3, 130.1,

129.4, 129.3, 129.1, 128.7, 127.5, 126.5, 114.8, 68.7, 63.4, 50.0, 21.7 ppm; IR (Neat): 3330, 2920, 1622, 1494, 1348, 1161, 1089, cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>25</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>4</sub>S [M+H]<sup>+</sup>: *m*/*z* 526.1310. Found: 526.1309.

## (E)-N-(2,3-dihydroxypropyl)-4-methoxy-N-(2-phenyl-2-(1-phenyl-1H-tetrazol-5-



yl)vinyl)benzenesulfonamide (5ca). Following the general procedure, the reaction of 3ca (89.9 mg, 0.2 mmol), BF<sub>3</sub> OEt<sub>2</sub> (5.0 µL, 0.04 mmol) and TMSN<sub>3</sub> (52.6 µL, 0.40 mmol) after column chromatography (EtOAc:hexane = 2:3) afforded **5ca** as a white solid. Yield 84 mg (83%). Mp 149-150  $^{\circ}$ C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.81-7.78 (m, 2H), 7.38-7.34 (m, 1H), 7.33-7.29

(m, 2H), 7.25 (s, 1H), 7.21-7.18 (m, 2H), 7.17-7.13 (m, 1H), 7.10-7.06 (m, 4H), 6.83-6.82 (m, 2H), 3.95 (s, 3H), 3.57-3.53 (m, 1H), 3.31-3.23 (m, 2H), 3.11-3.03 (m, 2H), 2.63 (bs, 1H), 2.07 (bs, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 163.7, 154.4, 133.8 132.5, 129.9, 129.8, 129.4, 129.1, 129.0, 128.6, 125.2, 114.9, 114.6, 68.5, 63.4, 55.9, 50.0 ppm; IR (Neat): 3372, 2945, 1594, 1497, 1344, 1256, 1153 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{25}H_{26}N_5O_5S$  [M+H]<sup>+</sup>: m/z508.1649. Found: 508.1647.

# (E)-N-(2-(1-(4-chlorophenyl)-1H-tetrazol-5-yl)-2-phenylvinyl)-N-(2,3-dihydroxypropyl)-4-

*methoxybenzenesulfonamide* (5cb). Following the general procedure, the reaction of 3cb (96.8



mg, 0.2 mmol), BF<sub>3</sub> OEt<sub>2</sub> (5.0 µL, 0.04 mmol) and TMSN<sub>3</sub> (52.6 µL, 0.40 mmol) after column chromatography (EtOAc:hexane = 2:3) afforded **5cb** as a white solid. Yield 85 mg (78%). Mp 152-153 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): § 7.83-7.80 (m, 2H), 7.32 (s, 1H), 7.27-7.24 (m, 2H), 7.21-7.18 (m, 1H), 7.14-7.11 (m, 4H), 7.10-7.07 (m, 2H), 6.82-6.81 (m, 2H), 3.96 (s, 3H), 3.59-3.56 (m, 1H), 3.32 (dd, J = 15.0, 8.0 Hz, 1H), 3.23 (dd, J = 11.5, 3.0 Hz, 1H), 3.10-3.04 (m,

2H), 2.81 (bs, 1H), 2.15 (bs, 1H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 163.8, 136.0 132.8, 132.4, 132.3, 129.8, 129.5, 129.3, 129.2, 128.7, 126.4, 114.6, 114.4, 68.6, 63.3, 55.8, 50.0 ppm; IR (Neat): 3300, 2922, 1623, 1594, 1495, 1346, 1251, 1157 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{25}H_{25}ClN_5O_5S$  [M+H]<sup>+</sup>: m/z 542.1249. Found: 542.1251.

## (E)-4-chloro-N-(2-(1-(4-chlorophenyl)-1H-tetrazol-5-yl)-2-phenylvinyl)-N-(2,3-

dihydroxypropyl)benzenesulfonamide (5db). Following the general procedure, the reaction of



**3db** (97.8 mg, 0.2 mmol), BF<sub>3</sub> OEt<sub>2</sub> (5.0 µL, 0.04 mmol) and TMSN<sub>3</sub> (52.6 µL, 0.40 mmol) after column chromatography (EtOAc:hexane = 2:3) afforded **5db** as a white solid. Yield 86 mg (79%). Mp 195-196 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.84 (d, J = 8.5 Hz, 2H), 7.60 (d, J = 8.5 Hz, 2H), 7.30 (s, 1H), 7.26 (d, J = 8.5 Hz, 2H), 7.22-7.19 (m, 1H), 7.15-7.10 (m, 4H), 6.81 (d,

J = 7.0 Hz, 2H), 3.60-3.58 (m, 1H), 3.36 (dd, J = 15.0, 8.5 Hz, 1H), 3.23 (dd, J = 11.3, 3.0 Hz, 1H), 3.10-3.03 (m, 2H), 2.82 (bs, 1H), 2.12 (bs, 1H) ppm; <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>): 155.0, 139.2 137.1, 135.1, 133.3, 133.0, 130.3, 129.7, 129.5, 129.1, 128.7, 128.0, 116.6, 69.2, 63.8, 51.3 ppm; IR (Neat): 3371, 2944, 1627, 1493, 1351, 1280, 1166 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>24</sub>H<sub>22</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>5</sub>S [M+H]<sup>+</sup>: m/z 546.0764. Found: 546.0768.

## (E)-N-(2,3-dihydroxypropyl)-2-nitro-N-(2-phenyl-2-(1-phenyl-1H-tetrazol-5-

yl)vinyl)benzenesulfonamide (5ea). Following the general procedure, the reaction of 3ea (93.1



mg, 0.2 mmol), BF<sub>3</sub> OEt<sub>2</sub> (5.0 μL, 0.04 mmol) and TMSN<sub>3</sub> (52.6 μL, 0.40 mmol) after column chromatography (EtOAc:hexane = 2:3) afforded **5ea** as a white solid. Yield 81 mg (78%). Mp 118-119 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.09 (d, J = 7.5 Hz, 1H), 7.79-7.71 (m, 3H), 7.39 (s, 1H), 7.23-

7.20 (m, 1H), 7.17-7.14 (m, 2H), 7.11-7.09 (m, 2H), 7.06-7.03 (m, 1H), 7.00-6.97 (m, 2H), 6.76

(d, J = 7.0 Hz, 2H), 3.62-3.61 (m, 1H), 3.38 (dd, J = 15.0, 9.0 Hz, 1H), 3.20 (dd, J = 11.5, 3.0 Hz, 2H), 3.06-3.02 (m, 2H), 2.34 (bs, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 154.4, 147.8 134.8, 133.6, 132.5, 132.2, 131.9, 131.5, 131.4, 129.9, 129.3, 129.1, 128.6, 125.3, 124.6, 115.1, 68.1, 63.5, 50.0 ppm; IR (Neat): 3341, 1541, 1479, 1363, 1163 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{24}H_{23}N_6O_6S$  [M+H]<sup>+</sup>: m/z 523.1394. Found: 523.1395.

(E)-N-(2-(1-(4-chlorophenyl)-1H-tetrazol-5-yl)-2-phenylvinyl)-N-(2,3-dihydroxypropyl)-2-

nitrobenzenesulfonamide (5eb). Following the general procedure, the reaction of 3eb (99.8 mg,



0.2 mmol), BF<sub>3</sub> OEt<sub>2</sub> (5.0 µL, 0.04 mmol) and TMSN<sub>3</sub> (52.6 µL, 0.40 mmol) after column chromatography (EtOAc:hexane = 2:3) afforded **5eb** as a white solid. Yield 85 mg (76%). Mp 89-90 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.18 (d, *J* = 7.5 Hz, 1H), 7.89-7.80 (m, 3H), 7.52 (s, 1H), 7.22-7.09 (m, 7H), 6.87 (d, *J* = 7.0 Hz, 2H), 3.76-3.69 (b, 1H), 3.50-3.42 (m,

1H), 3.35-3.25 (m, 2H), 3.16-3.08 (m, 2H), 2.33 (bs, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 154.5, 147.9 136.0, 134.8, 132.5, 132.2, 132.1, 132.0, 131.6, 131.4, 129.4, 129.3, 128.8, 126.6, 124.7, 114.0, 68.1, 63.4, 49.9 ppm; IR (Neat): 3350, 2922, 1619, 1541, 1495, 1364, 1165 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{24}H_{22}ClN_6O_6S [M+H]^+$ : m/z 557.1005. Found: 557.1006.

(E)-N-(2,3-dihydroxypropyl)-N-(2-phenyl-2-(1-phenyl-1H-tetrazol-5-yl)vinyl)thiophene-2-

sulfonamide (5fa). Following the general procedure, the reaction of 3fa (85.1 mg, 0.2 mmol),



BF<sub>3</sub>·OEt<sub>2</sub> (5.0 µL, 0.04 mmol) and TMSN<sub>3</sub> (52.6 µL, 0.40 mmol) after column chromatography (EtOAc:hexane = 2:3) afforded **5fa** as a white solid. Yield 79 mg (82%). Mp 150-151 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  7.77 (dd, J = 5.0, 3.0 Hz, 1H), 7.70 (dd, J = 4.0, 1.5 Hz, 1H), 7.37-7.33 (m, 1H), 7.31-

7.30 (m, 2H), 7.24-7.20 (m, 4H), 7.17-7.14 (m, 1H), 7.11-7.08 (m, 2H), 6.82-6.81 (m, 2H), 3.62-

3.58 (m, 1H), 3.36-3.27 (m, 2H), 3.14 (dd, J = 11.5, 5.0 Hz, 1H), 3.06 (dd, J = 15.5, 4.5 Hz, 1H), 2.83 (bs, 1H), 2.23 (bs, 1H) ppm; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): 154.1, 137.9 133.7, 133.5, 133.3, 132.3, 131.8, 130.0, 129.3, 129.2, 128.7, 128.0, 125.1, 117.6, 68.6, 63.3, 50.6 ppm; IR (Neat): 3381, 2922, 1605, 1495, 1357, 1158 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{22}H_{22}N_5O_4S_2$ [M+H]<sup>+</sup>: m/z 484.1108. Found: 484.1106.

# (E) - N - (2, 3 - dihydroxy propyl) - N - (2 - phenyl - 2 - (1 - phenyl - 1H - tetrazol - 5 - yl) vinyl) naphthalene - 2 - (1 - phenyl -

sulfonamide (5ga). Following the general procedure, the reaction of 3ga (93.9 mg, 0.2 mmol),

BF<sub>3</sub>·OEt<sub>2</sub> (5.0 μL, 0.04 mmol) and TMSN<sub>3</sub> (52.6 μL, 0.40 mmol) after column chromatography (EtOAc:hexane = 2:3) afforded **5ga** as a white solid. Yield 81 mg (77%). Mp 66-67 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 8.46 (s, 1H), 8.06-8.03 (m, 2H), 7.99 (d, J = 8.0 Hz, 1H), 7.81-7.79 (m, 1H), 7.75-7.67 (m, 2H), 7.37 (s, 1H), 7.26-7.23 (m, 1H), 7.13-7.04 (m, 5H), 6.96-6.93 (m, 2H), 6.63 (d, J = 7.0 Hz, 2H), 3.61-3.58 (m, 1H), 3.66 (dd, J = 15.0, 8.0 Hz, 1H), 3.25 (dd, J = 11.5, 3.0 Hz, 1H), 3.12-3.04 (m, 2H), 2.88 (bs, 1H), 2.21 (bs, 1H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 154.3, 135.2 134.9, 133.7, 132.4, 132.2, 129.8, 129.5<sub>0</sub>, 129.4<sub>5</sub>, 129.3, 129.1, 129.0<sub>4</sub>, 128.9<sub>7</sub>, 128.5, 128.1, 125.1, 122.2, 115.6, 68.7, 63.3, 50.1 ppm; IR (Neat): 3391, 2922, 1730, 1618, 1498, 1347, 1158 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>28</sub>H<sub>26</sub>N<sub>5</sub>O<sub>4</sub>S [M+H]<sup>+</sup>: *m*/z 528.1700. Found: 528.1706.

# 4. (d) Synthesis of tetrahydropyridine-3-carbaldehydes 6hc-kc: *Representative procedure for the synthesis of compound 6hc*



To a mixture of (Z)-3-chloro-3-(4-nitrophenyl)acrylaldehyde 2c (63.5 mg, 0.30 mmol, 1.0 equiv) and K<sub>2</sub>CO<sub>3</sub> (82.9 mg, 0.60 mmol, 2.0 equiv) in dry DMF (5 mL), N-((2-methyloxiran-2yl)methyl)benzenesulfonamide 1h (79.0 mg, 0.36 mmol, 1.2 equiv) was added. The resulting mixture was heated for 2 h on an oil-bath maintained at 80 °C. After the completion of the reaction as monitored by TLC, ethyl acetate (30 mL) was added and the solution was washed with water  $(3 \times 30 \text{ mL})$  and then with brine solution  $(3 \times 15 \text{ mL})$ ; the aqueous layer was extracted with ethyl acetate (3  $\times$  20 mL). The combined organic portion was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, the solvent was evaporated under the reduced pressure. This whole residue was dissolved in in dry CHCl<sub>3</sub> (2 ml), and BF<sub>3</sub> OEt<sub>2</sub> (5.0 µL, 0.04 mmol, 0.2 equiv) was added. The resulting mixture was stirred for 3 h at rt (25 °C). After the completion of the reaction as monitored by TLC, DCM (10 mL) was added and the solution was washed with water (3  $\times$  10 mL), then brine solution  $(3 \times 10 \text{ mL})$ ; the aqueous layer was extracted with DCM  $(3 \times 10 \text{ mL})$ . The combined organic portion was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under the reduced pressure, and the residue was purified by column chromatography on silica gel (eluent: hexane/ethyl acetate 1: 4) to obtain compound **6hc** as a light-yellow solid. Using the same molar quantities, the remaining compounds were prepared.

5-formyl-3-methyl-6-(4-nitrophenyl)-1-(phenylsulfonyl)-1,2,3,4-tetrahydropyridin-4-yl)oxy)-5methyl-2-(4-nitrophenyl)-1-(phenylsulfonyl)-1,4,5,6-tetrahydropyridine-3-carbaldehyde (6hc).



Yellow solid. Yield 65 mg (83%). Mp 167-168 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.80 (s, 2H), 8.21 (dd,  $J_1$  = 8.0 Hz,  $J_2$  = 2.0 Hz, 2H), 7.86 (dd,  $J_1$  = 8.0 Hz,  $J_2$  = 2.0 Hz, 2H), 7.59-7.56 (m, 2H), 7.46 (dd,  $J_1$  = 8.5 Hz,  $J_2$  = 1.5 Hz, 2H), 7.39-7.33 (m,

8H), 6.96 (dd,  $J_1 = 8.5$  Hz,  $J_2 = 1.5$  Hz, 2H), 4.43 (d, J = 12.0 Hz, 2H), 4.20 (s, 2H), 3.48 (dd,  $J_1 = 12.5$  Hz,  $J_2 = 2.0$  Hz, 2H), 2.96-2.95 (m, 2H), 0.97 (d, J = 7.0 Hz, 6H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 190.0, 153.8, 148.3 140.4, 137.5, 133.7, 133.4, 130.8, 129.1, 126.9, 122.6, 122.1, 120.5, 68.0, 48.2, 27.5, 13.8 ppm; IR (Neat): 2968, 1737, 1664, 1645, 1510, 1367, 1346, 1164 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>38</sub>H<sub>35</sub>N<sub>4</sub>O<sub>11</sub>S<sub>2</sub> [M+H]<sup>+</sup>: *m*/*z* 787.1738. Found: 787.1732.

5-formyl-3-methyl-6-(4-nitrophenyl)-1-tosyl-1,2,3,4-tetrahydropyridin-4-yl)oxy)-5-methyl-2-(4nitrophenyl)-1-tosyl-1,4,5,6-tetrahydropyridine-3-carbaldehyde (6ic). White solid. Yield 63 mg



12.0 Hz, 2H), 2.97-2.96 (m, 2H), 2.44 (s, 6H), 0.97 (d, J = 7.0 Hz, 6H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 190.0, 154.0, 148.3, 145.0, 137.7, 137.4, 133.3, 130.8, 129.7, 127.0, 122.5, 122.1, 120.2, 68.0, 48.1, 27.5, 21.6, 13.8 ppm; IR (Neat): 2969, 2861, 1738, 1552, 1343, 1315, 1149 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>40</sub>H<sub>39</sub>N<sub>4</sub>O<sub>11</sub>S<sub>2</sub> [M+H]<sup>+</sup>: m/z 815.2051. Found: 815.2055.

5-formyl-6-(4-nitrophenyl)-3-phenyl-1-tosyl-1,2,3,4-tetrahydropyridin-4-yl)oxy)-2-(4-

nitrophenyl)-5-phenyl-1-tosyl-1,4,5,6-tetrahydropyridine-3-carbaldehyde (6jc). White solid.



Yield 71 mg (76%). Mp 138-139 °C; <sup>1</sup>H NMR (500 MHz, <sup>Ae</sup> CDCl<sub>3</sub>):  $\delta$  8.85 (s, 2H), 8.26 (d, J = 7.0 Hz, 2H), 7.99 (d, J= 7.5 Hz, 2H), 7.49 (d, J = 7.5 Hz, 2H),7.34 (s, 6H), 7.20 (d, J = 5.0 Hz, 4H), 6..96 (d, J = 8.0 Hz, 4H), 6.90 (d, J =

8.0 Hz, 2H), 6.71 (d, J = 8.0 Hz, 4H), 4.89 (s, 2H), 4.78 (d, J = 12.5 Hz, 2H), 4.22 (s, 2H), 3.92-3.89 (m, 2H), 2.38 (s, 6H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 189.3, 155.3, 148.3, 144.9, 138.2, 137.0, 136.4, 132.2, 132.0, 129.5, 128.8, 127.6, 127.3, 127.2, 122.2, 120.0, 65.8, 48.3, 38.0, 21.6 ppm; IR (Neat): 2921, 2852, 1734, 1656, 1521, 1345, 1163 cm<sup>-1</sup>; HRMS (ESI): Calcd. for  $C_{50}H_{42}N_4NaO_{11}S_2 [M+Na]^+$ : m/z 961.2184. Found: 961.2181.

# 5-formyl-1-((4-methoxyphenyl)sulfonyl)-3-methyl-6-(4-nitrophenyl)-1,2,3,4-tetrahydropyridin-4-yl)oxy)-1-((4-methoxyphenyl)sulfonyl)-5-methyl-2-(4-nitrophenyl)-1,4,5,6-

tetrahydropyridine-3-carbaldehyde (6kc). Yellow solid. Yield 61 mg (72%). Mp 165-166 °C; <sup>1</sup>H



NMR (500 MHz, CDCl<sub>3</sub>): δ 8.81 (s, 2H), 8.22 (d, *J* = 8.0 Hz, 2H), 7.95 (d, *J* = 7.5 Hz, 2H), 7.60 (d, *J* = 8.0 Hz, 2H), 7.26 (s, 4H), 7.07 (d, *J* = 7.5 Hz, 2H), 6.83 (d, *J* = 8.5 Hz, 4H), 4.40 (d, *J* = 12.5 Hz, 2H), 4.21 (s, 2H), 3.88 (s, 6H), 3.48 (d,

J = 12.5 Hz, 2H), 2.96-2.95 (m, 2H), 0.97 (d, J = 7.0 Hz, 6H) ppm; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 190.0, 163.8, 154.1, 148.3, 137.8, 133.2, 131.7, 130.9, 129.3, 122.5, 122.1, 120.0, 114.2, 68.0, 55.9, 48.0, 27.6, 13.9 ppm; IR (Neat): 2924, 1656, 1564, 1494, 1345, 1267, 1160 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>40</sub>H<sub>38</sub>NaN<sub>4</sub>O<sub>13</sub>S<sub>2</sub> [M+Na]<sup>+</sup>: m/z 869.1769. Found: 869.1773.

# 4. (e) Synthesis of tetrahydropyridin-3-yl benzoate 7la:



# 4,5-diphenyl-1-tosyl-1,2,3,4-tetrahydropyridin-3-yl benzoate (71a). The procedure was the same

as described earlier for azabicyclononenes 4aa-gb. Thus the reaction of 3la (101.9 mg, 0.2



mmol) with BF<sub>3</sub>OEt<sub>2</sub> (5.0 µL, 0.04 mmol) after column chromatography (EtOAc:hexane = 1:9) afforded **7la** as a white solid. Yield 66 mg (65%). Mp 169-170 °C; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ 7.73-7.66 (m, 5H), 7.55-7.52 (m, 1H), 7.36-7.33 (m, 2H), 7.28 (d, J = 8.0 Hz, 2H), 7.24-7.21 (m, 5H), 7.15-7.12 (m, 5H), 5.34 (s, 1H), 4.12 (s, 1H), 3.97 (d, J = 13.5 Hz, 1H), 3.27 (d, J = 13.5 Hz, 1H), 2.23 (s, 3H) ppm; <sup>13</sup>C NMR (125

MHz, CDCl<sub>3</sub>): 165.7, 143.9, 139.9. 138.7, 134.9, 133.2, 129.9, 129.7, 129.5, 128.9, 128.6, 128.4, 128.2, 127.5, 127.1, 126.7, 125.1, 123.0, 115.1, 70.7, 44.6, 41.6, 21.5 ppm; IR (Neat): 3056, 1713, 1647, 1599, 1451, 1348, 1263, 1162 cm<sup>-1</sup>; HRMS (ESI): Calcd. for C<sub>31</sub>H<sub>28</sub>NO<sub>4</sub>S [M+H]<sup>+</sup>: m/z 510.1734. Found: 510.1731. Crystallization was done from ethyl acetate-hexane mixture (1:20).

(5) Crystal data and molecular structures



**Figure S1.** ORTEP view of 3,4-diphenyl-9-(phenylsulfonyl)-2,6-dioxa-9-azabicyclo[3.2.2]non-3-ene **4aa** with 30% probability of ellipsoids. *Crystal data:* C<sub>24</sub>H<sub>21</sub>NO<sub>4</sub>S, M = 419.48, Orthorhombic, Space group P 2(1) 2(1) 2(1), a = 5.9615(2), b = 14.5594(7), c = 23.8714(11) Å, V = 2071.92(16)Å<sup>3</sup>,  $\alpha = 90$ ,  $\beta = 90$ ,  $\gamma = 90^{\circ}$ , Z = 4,  $\mu = 0.187$  mm<sup>-1</sup>, data/restraints/parameters: 3376/0/265, R indices (>2sigma(I)): R1 = 0.0952, *w*R2 (all data) = 0.2916. Selected bond parameters: S1-N1 1.616(8), N1-C1 1.467(10), N1-C6 1.504(12), O2-C1 1.420(11), O2-C5 1.442(12), C4-C5 1.495(14), C4-C6 1.509(13), C1-C2 1.530(13), C3-C2 1.339(14), O1-C3 1.387(11), O1-C4 1.470(11), C2-C13 1.507(13), C3-C7 1.466(15) (Å). CCDC No: 2237334.



**Figure S2.** ORTEP view of 3-(4-chlorophenyl)-9-((4-chlorophenyl)sulfonyl)-4-phenyl-2,6dioxa-9-azabicyclo[3.2.2]non-3-ene **4db** with 30% probability of ellipsoids. *Crystal data:*  $C_{24}H_{19}Cl_2NO_4S$ , M = 488.39, Monoclinic, Space group P 1 21/c 1, a = 12.9092(17), b = 6.0215(7), c = 29.195(4) Å, V = 2242.7(5)Å<sup>3</sup>,  $\alpha = 90$ ,  $\beta = 98.799$  (5),  $\gamma = 90^{\circ}$ , Z = 4,  $\mu = 0.415$  mm<sup>-1</sup>, data/restraints/parameters: 5135/0/289, R indices (>2sigma(I)): R1 = 0.0490 (3649), wR2 (all data) = 0.1441 (5135). Selected bond parameters: S1-N1 1.6464(19, N1-C12 1.465(3), N1-C10 1.480(3), O2-C12 1.427(3), O2-C11 1.448(4), C9-C10 1.500(4), C9-C11 1.515(4), C1-C12 1.517(3), C1-C2 1.338(3), O1-C9 1.446(3), O1-C2 1.373(3), C3-C2 1.493(3), C1-C19 1.490(3) (Å). CCDC No: 2237335



Molecule-1 (5ba)

Molecule-2 (5ba)

**Figure S3.** ORTEP view of (*E*)-*N*-(2,3-dihydroxypropyl)-4-methyl-N-(2-phenyl-2-(1-phenyl-1H-tetrazol-5-yl)vinyl)benzenesulfonamide **5ba** with 30% probability of ellipsoids. *Crystal data:*  $C_{25}H_{24}N_5O_4S$ , M = 491.56, Monoclinic, Space group P 1 21/c 1, *a* = 20.3465(7), *b* = 10.9821(3), *c* = 23.9221(9) Å, *V* = 4954.2(3) Å<sup>3</sup>, *a* = 90, *β* = 112.054 (4),  $\gamma = 90^{\circ}$ , *Z*= 4,  $\mu = 0.172$  mm<sup>-1</sup>; data/restraints/parameters: 8741/0/631, R indices (I> 2sigma(I)): R1 = 0.1008 (5049), wR2 (all data) = 0.3473 (8741). Selected bond parameters: S1-N1 1.642(5), N1-C15 1.423(7), N1-C23 1.487(8), C23-C24 1.492(9), C24-C25 1.434(9), C8-C7 1.461(8), C9-C8 1.469(7), C8-C15 1.343(7), O4-C24 1.466(8), O3-C25 1.422(9), C7-N2 1.340(8), N5-C7 1.335(8), N5-C1 1.444(10), N2-N3 1.347(8), N4-N3 1.268(9), N5-N4 1.379(8) (Å). Molecule-2: S2-N6 1.646(5), N6-C48 1.477(7), N6-C40 1.408(7), C48-C49 1.380(12), C50-C49 1.321(12), C33-C40 1.340(7), C34-C33 1.481(7), C33-C32 1.470(7), O7-C49 1.446(10), O8-C50 1.400(11), N11-C32 1.327(7), N8-C26 1.440(7), N8-C32 1.333(6), N8-N9 1.348(6), N9-N10 1.272(7), N11-N11 1.371(7). CCDC No: 2237336.



**Figure S4.** ORTEP view of (*E*)-*N*-(2-(1-(4-chlorophenyl)-1H-tetrazol-5-yl)-2-phenylvinyl)-N-(2,3-dihydroxypropyl)-4-methoxybenzenesulfonamide **5cb** with 30% probability of ellipsoids. *Crystal data:* C<sub>25</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>5</sub>S, M = 542.00, Triclinic, Space group P1, *a* = 10.4254(3), *b* = 11.9858(4), *c* = 12.4011(3) Å, *V* = 1403.61(8) Å<sup>3</sup>, *a* = 69.515(3), *β* = 75.700(3), *γ* = 88.454(3)°, *Z*= 2,  $\mu$  = 0.398 mm<sup>-1</sup>; data/restraints/parameters: 5921/0/331, R indices (I> 2sigma(I)): R1 = 0.0530 (3605), wR2 (all data) = 0.1622 (5921). Selected bond parameters: S1-N5 1.6622(18), N5-C23 1.487(2), N5-C15 1.395(3), C24-C23 1.528(3), C24-C25 1.503(3), C8-C15 1.343(3), C8-C9 1.475(3), C8-C7 1.456(3), O4-C25 1.412(3), O3-C24 1.411(2), N1-C7 1.355(3), N1-C6 1.423(3), N1-N2 1.365(2), N2-N3 1.273(3), N4-N3 1.363(3), N4-C7 1.320(3) (Å) CCDC No: 2237337



**Figure S5.** ORTEP view of 5-formyl-3-methyl-6-(4-nitrophenyl)-1-(phenylsulfonyl)-1,2,3,4-tetrahydropyridin-4-yl)oxy)-5-methyl-2-(4-nitrophenyl)-1-(phenylsulfonyl)-1,4,5,6-

tetrahydropyridine-3-carbaldehyde **6hc** with 30% probability of ellipsoids. *Crystal data:*  $C_{38}H_{34}N_4O_{11}S_2$ , M = 786.81, orthorhombic, Space group P b c n, a = 25.8268(11), b = 16.2750(7), c = 10.0472(5) Å, V = 4223.2 (3) Å<sup>3</sup>, a = 90,  $\beta = 90$ ,  $\gamma = 90$ , Z = 4,  $\mu = 0.185$  mm<sup>-1</sup>, data/restraints/parameters: 3723/0/244, R indices (I> 2sigma(I)): R1 = 0.0579 (2260), wR2 (all data) = 0.1784 (3723). Selected bond parameters: S1-N1 1.677(2), N1-C7 1.475(4), N1-C11 1.399(4), C7-C8 1.519(4), C9-C8 1.515(4), C9-C10 1.492(4), C11-C10 1.348(4), C10-C18 1.463(5), C11-C12 1.493(4), O1-C9 1.445(3) (Å) CCDC No: 2237338.


Molecule-1 (7la)

Molecule-2 (7la)

**Figure S6.** ORTEP view of 4,5-diphenyl-1-tosyl-1,2,3,4-tetrahydropyridin-3-yl benzoate **71a** with 30% probability of ellipsoids. *Crystal data:* C<sub>31</sub>H<sub>27</sub>NO<sub>4</sub>S, M = 509.59, Triclinic, Space group  $P\overline{1}$ , a = 7.1998(5), b = 16.6494(10), c = 21.1710(14) Å, V = 2652.7(3) Å<sup>3</sup>, a = 76.121(5),  $\beta = 83.698$  (5),  $\gamma = 89.177(5)^{\circ}$ , Z = 4,  $\mu = 0.159$  mm<sup>-1</sup>; data/restraints/parameters: 8720/578/669, R indices (I> 2sigma(I)): R1 = 0.0954 (3545), wR2 (all data) = 0.3113 (8720). Selected bond parameters: S1-N1 1.642(5), N1-C1 1.465(7), N1-C5 1.414(7), C2-C1 1.509(7), C3-C2 1.525(7), C4-C3 1.497(7), C4-C5 1.333(7), O1-C2 1.459(6), O1-C25 1.359(7), O2-C25 1.201(7) (Å). Molecule-2: S2-N2 1.643(5), N2-C32 1.394(7), N2-C36 1.467(7), C32-C33 1.326(7), C34-C33 1.491(7), C34-C35 1.539(7), C35-C36 1.508(7), O5-C35 1.458(6), O5-C56 1.351(7), O6-C56 1.211(7) (Å). CCDC No: 2253326.

## (6) References

- (1) Perrin, D. D.; Armarego, W. L. F.; Perrin, D. R. *Purification of Laboratory Chemicals*, pergamon, Oxford, UK, **1986**.
- (2) (a) Sheldrick, G. M. SADABS, Siemens Area Detector Absorption Correction, University of Gottingen, Germany, 1996. (b) Sheldrick, G. M., SHELX-97-A program for crystal structure solution and refinement, University of Gottingen, 1997. (c) Sheldrick, G. M.SHELXTL NT Crystal analysis package, Bruker AXS, Analytical X-ray system, WI, USA, 1999, version 5.10.
- (3) J. Rintjema, R. Epping, G. Fiorani, E. Martín, E. C. Escudero-Adán, A. W. Kleij, *Angew.Chem. Int. Ed.* **2016**, *55*, 3972.
- (4) Ni, Z.; Giordano, L.; Tenaglia, A. Cyclobutene Formation in PtCl<sub>2</sub>-Catalyzed Cycloisomerizations of Heteroatom-Tethered 1,6-Enynes.*Chemistry-A European Journal*. 2014, 20, 11703-11706.
- (5) Olivares-Romero, J. L.; Li, Z.; Yamamoto, H. Hf(IV)-Catalyzed Enantioselective Epoxidation of *N*-Alkenyl Sulfonamides and *N*-TosylImines. *J. Am. Chem. Soc.* 2012, 134, 5440–5443.
- (6) (a) Hu, J.; Cheng, Y.; Yang, Y.; Rao, Yu. A general and efficient approach to 2*H*-indazoles and 1*H*-pyrazoles through copper-catalyzed intramolecular *N*–*N* bond formation under mild conditions. *Chem. Commun.* 2011, 47, 10133–10135. (b) Scholz, M.; Ulbrich, H K.; Dannhardt, G. Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. *Eur. J. Med. Chem.* 2008, 43, 1152-1159.
- (7) Suraj and Kumara Swamy, K. C. Ring-Expansion Reactions of Epoxy Amides and Enamides: Functionalized Azetidines, Dihydrofurans, Diazocanes, or Dioxa-3azabicyclonon-4-enes? J. Org. Chem. 2022, 87, 6612-6629.



Figure S8. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3aa



Figure S10. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3ab



Figure S12. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3ba



Figure S14. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3bb



Figure S16. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3ca



Figure S18. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3cb



Figure S20. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3da



Figure S22. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3db



Figure S24. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3ea



Figure S26. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3eb



Figure S28. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3fa



Figure S30. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3fb



Figure S32. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3ga



Figure S34. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3gb



Figure S36. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 3la



Figure S38. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4aa



Figure S40. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4ab



Figure S42. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4ba



Figure S44. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4bb



Figure S46. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4ca



Figure S48. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4cb





Figure S50. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4da

 $\begin{array}{c} 7.813\\ -7.719\\ -7.719\\ -7.719\\ -7.728\\$ 



Figure S52. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4db





Figure S54. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4ea



Figure S56. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4eb



Figure S58. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4fa



Figure S60. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4fb



Figure S62. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4ga



Figure S64. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 4gb



Figure S66. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 5aa



Figure S68. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 5ba



Figure S70. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 5bb



Figure S72. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 5ca



Figure S74. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 5cb
7,3447,75957,75957,75957,75957,75957,72087,72097,



Figure S76. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 5db



Figure S78. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 5ea



Figure S80. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 5eb



Figure S82. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 5fa





Figure S84. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 5ga



Figure S86. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 6hc



Figure S88. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 6ic



Figure S90. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 6jc



Figure S92. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 6kc



Figure S94. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum of compound 7la